Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12610000378022
Ethics application status
Approved
Date submitted
10/05/2010
Date registered
11/05/2010
Date last updated
14/10/2015
Type of registration
Prospectively registered
Titles & IDs
Public title
Effect of metformin on lung function in diabetic or prediabetic individuals with respiratory disease
Query!
Scientific title
The effect of oral metformin on spirometry, exercise capacity and quality of life in adults with chronic obstructive pulmonary disease (COPD) and either diet-controlled type 2 diabetes mellitus or impaired glucose tolerance.
Query!
Secondary ID [1]
251712
0
None
Query!
Universal Trial Number (UTN)
U1111-1114-9527
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Chronic obstructive pulmonary disease
257316
0
Query!
Type 2 diabetes mellitus
257317
0
Query!
Impaired glucose tolerance
257318
0
Query!
Insulin resistance
257319
0
Query!
Condition category
Condition code
Respiratory
257460
257460
0
0
Query!
Chronic obstructive pulmonary disease
Query!
Metabolic and Endocrine
257461
257461
0
0
Query!
Diabetes
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Oral metformin 850mg twice daily for 6 months.
Query!
Intervention code [1]
256439
0
Treatment: Drugs
Query!
Comparator / control treatment
Not applicable
Query!
Control group
Uncontrolled
Query!
Outcomes
Primary outcome [1]
258380
0
Change in forced expiratory volume in first second (FEV1), measured using spirometer
Query!
Assessment method [1]
258380
0
Query!
Timepoint [1]
258380
0
Baseline, 6 weeks, 12 weeks, 18 weeks, 24 weeks
Query!
Secondary outcome [1]
264114
0
Change in incremental shuttle walk distance
Query!
Assessment method [1]
264114
0
Query!
Timepoint [1]
264114
0
Baseline and 24 weeks
Query!
Secondary outcome [2]
264115
0
change in respiratory quality of life score (St George Respiratory questionnaire)
Query!
Assessment method [2]
264115
0
Query!
Timepoint [2]
264115
0
Baseline and 24 weeks
Query!
Eligibility
Key inclusion criteria
* Obese (body mass index > 30)
* Central pattern of obesity (elevated waist circumference)
* Impaired glucose tolerance or diet-controlled type 2 diabetes mellitus (previous diagnosis, or evidence of blood tests meeting American Diabetes Association 2010 criteria)
* Post-bronchodilator spirometry that is consistent with Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage 2+ COPD
* Symptomatic: Medical Research Council dyspnoea score of 2 or higher
Query!
Minimum age
45
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. Currently taking oral hypoglycaemic agent or insulin
2. Active respiratory disease other than obstructive airways disease
3. Exacerbation of airways disease requiring change in treatment within the preceding 6 weeks
4. Participation in pulmonary rehabilitation programme within the past 6 weeks
5. Currently prescribed long term oral corticosteroids
6. Renal impairment (estimated glomerular filtration rate < 45 mL/min)
7. Cirrhosis, impaired synthetic liver function, or liver failure
8. Chronic respiratory failure
9. Congestive heart failure
10. Current or recent habitual heavy alcohol intake
11. Current use of antiretroviral medication
12. Pregnancy
13. History of lactic acidosis
14. Allergy to metformin
15. Unable to comply with the study procedures or protocol
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Potential subjects are identified from outpatient records.
Allocation is not concealed.
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
N/A
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
N/A
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Efficacy
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Date of first participant enrolment
Anticipated
1/03/2011
Query!
Actual
9/06/2011
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
7/05/2012
Query!
Date of last data collection
Anticipated
Query!
Actual
Query!
Sample size
Target
40
Query!
Accrual to date
Query!
Final
17
Query!
Recruitment outside Australia
Country [1]
2619
0
New Zealand
Query!
State/province [1]
2619
0
Query!
Funding & Sponsors
Funding source category [1]
256930
0
Charities/Societies/Foundations
Query!
Name [1]
256930
0
Greenlane Research and Educational Fund
Query!
Address [1]
256930
0
Auckland City Hospital
Cardiology Department
Level 3, Building 32
Park Road
Grafton
AUCKLAND, 1142
Query!
Country [1]
256930
0
New Zealand
Query!
Primary sponsor type
Individual
Query!
Name
Dr Paul Sexton
Query!
Address
Department of Medicine, Building 599, Faculty of Medical & Health Sciences, University of Auckland
PO Box 92019
Grafton
Auckland 1023
Query!
Country
New Zealand
Query!
Secondary sponsor category [1]
256196
0
Individual
Query!
Name [1]
256196
0
Prof John Kolbe
Query!
Address [1]
256196
0
Department of Medicine, Building 599, Faculty of MEdical & Health Sciences, University of Auckland
PO Box 92019
Grafton
Auckland 1023
Query!
Country [1]
256196
0
New Zealand
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
258934
0
Northern Y Regional Ethics Committee
Query!
Ethics committee address [1]
258934
0
3rd floor, BNZ building 354 Victoria St PO Box 1031 Hamilton
Query!
Ethics committee country [1]
258934
0
New Zealand
Query!
Date submitted for ethics approval [1]
258934
0
01/06/2010
Query!
Approval date [1]
258934
0
14/09/2010
Query!
Ethics approval number [1]
258934
0
Query!
Summary
Brief summary
Diabetes mellitus is known to cause damage to many organs, but its effects of the lungs are underrecognised. Diabetes is commonly associated with reduced lung volumes and impairment of other aspects of respiratory function; the cause is unknown. The effect of antidiabetic treatments on respiratory function is also largely unknown. Metformin is an oral antidiabetic agent which improves blood sugar levels and directly improves insulin resistance. Metformin is also safe for use in prediabetic and nondiabetic individuals. If metformin can improve lung function in diabetes, this could provide a way to treat diabetic and prediabetic patients with cardiorespiratory disease, as well as providing information about how diabetes affects respiratory function. We plan to evaluate the effect of 6 months of metformin treatment on lung volumes and other relevant outcomes in a group of 40 subjects with chronic obstructive pulmonary disease (COPD, emphysema) and impaired glucose tolerance or diet-controlled diabetes.
Query!
Trial website
Query!
Trial related presentations / publications
Sexton P, Metcalf P, Kolbe J. Respiratory Effects of Insulin Sensitisation with Metformin: A Prospective Observational Study. COPD 2013 Jul 12. PMID: 23848509
Query!
Public notes
Query!
Contacts
Principal investigator
Name
31137
0
Dr Paul Sexton
Query!
Address
31137
0
Department of Medicine, Faculty of Medical & Health Sciences, Building 599, University of Auckland PO Box 92019 Grafton Auckland 1023
Query!
Country
31137
0
New Zealand
Query!
Phone
31137
0
+64-9-9237290
Query!
Fax
31137
0
Query!
Email
31137
0
[email protected]
Query!
Contact person for public queries
Name
14384
0
Dr Paul Sexton
Query!
Address
14384
0
Department of Medicine, Faculty of Medical & Health Sciences, Building 599, University of Auckland
PO Box 92019
Grafton
Auckland 1023
Query!
Country
14384
0
New Zealand
Query!
Phone
14384
0
+64-9-9237290
Query!
Fax
14384
0
Query!
Email
14384
0
[email protected]
Query!
Contact person for scientific queries
Name
5312
0
Dr Paul Sexton
Query!
Address
5312
0
Department of Medicine, Faculty of Medical & Health Sciences, Building 599, University of Auckland
PO Box 92019
Grafton
Auckland 1023
Query!
Country
5312
0
New Zealand
Query!
Phone
5312
0
+64-9-9237290
Query!
Fax
5312
0
Query!
Email
5312
0
[email protected]
Query!
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF